Elsevier

Advances in Immunology

Volume 74, 1999, Pages 181-273
Advances in Immunology

Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance

https://doi.org/10.1016/S0065-2776(08)60911-6Get rights and content

Publisher Summary

It is known for some time that malignant transformation of human cells may be associated with the appearance of tumor associated antigens (TAA). Decades of research have been aimed at the identification of TAA that can serve as targets for the immunotherapy of malignant diseases. The dramatic progress in the understanding of molecular basis of target cell recognition by cytotoxic T lymphocytes (CTL) has provided the background to design effective strategies to identify TAA recognized by CTL on tumor cells. The extensive application of these strategies by a number of investigators has resulted in the identification of various families of TAA on various types of solid tumors. Mouse tumor models have played an important role in elucidating the mechanisms by which the immune system interacts with tumor cells and eradicates cancer. The second line of evidence is represented by the phenomenon of a “mixed response.” A mixed response occurs rather frequently in patients with metastases, although its actual frequency is not documented. Mixed responses are characterized by the different behavior of synchronous metastases in response to T cell-based immunotherapy. This important finding suggests that TAA-specific CTL may be present in some cancer patients but are unable to attack tumor cells due to the presence of inhibitory receptors.

References (444)

  • M. Clerici et al.

    The Th1-Th2 hypothesis of HIV infection: new insights

    Immunol. Today

    (1994)
  • G. D'Alessandro et al.

    Immuno-histological evaluation of MHC class I and II antigen expression on nevi and melanoma: Relation to biology of melanoma

    Pathology

    (1987)
  • R. Akella et al.

    Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines does not correlate with their susceptibility to natural killer cell-mediated cytolysis: evidence for additional ligands for effector cell beta integrins

    Eur. J. Immunol.

    (1992)
  • E.T. Akporiaye et al.

    Functional class II antigen presentation pathway in metastatic melanoma cell lines

    J. Immunother.

    (1996)
  • M.L. Albert et al.

    Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

    Nature

    (1998)
  • A.P. Albino et al.

    Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens

    J. Exp. Med.

    (1981)
  • M.A. Alexander-Miller et al.

    Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL

    J. Exp. Med.

    (1996)
  • D.S. Allan et al.

    Tetrameric complexes of HLA-G bind to peripheral blood myclomonocytic cells

    J. Exp. Med.

    (1999)
  • R.S. Alpan et al.

    Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line

    Cancer Res.

    (1996)
  • J.D. Altman et al.

    Phenotypic analysis of antigen-specific T lymphocytes [published erratum, Science 1998; 280(5371):1821]

    Science

    (1996)
  • M. Altomonte et al.

    Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells

    Cancer Res.

    (1993)
  • H. Arai et al.

    Gene transfer of Fas ligand induces tumor regression in vivo

    Proc. Natl. Acad. Set. USA

    (1997)
  • T.D. Armstrong et al.

    MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes

    J. Immunol.

    (1998)
  • D.W. Bahler et al.

    Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection

    Proc. Natl. Acad. Sci. USA

    (1987)
  • N.H. Bander et al.

    MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma

    Prostate

    (1997)
  • BeckerJ.C. et al.

    Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity

    J.Immunol.

    (1991)
  • M.T. Bedford et al.

    Hypomethylation of DNA in pathological conditions of the human prostate

    Cancer Res.

    (1987)
  • G. Bellone et al.

    Regulation of NK cell functions by TGF-beta 1

    J. Immunol.

    (1995)
  • R. Benitez et al.

    Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

    Tissue Antigens

    (1998)
  • M.W. Bennett et al.

    The Fas counterattack in vivo: Apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma

    J. Immunol.

    (1998)
  • M. Bettinotti et al.

    Stringent allele/epitope requirements for MART–1/Melan A immunodommance: implications for peptide-based imrmmotherapy

    J. Immunol.

    (1998)
  • N. Bhardwaj et al.

    Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells

    J. Clin. Invest.

    (1994)
  • BicknellD.C. et al.

    Beta 2-microglobulin gene mutations: A study of established colorectal cell lines and fresh tumors

    Proc. Natl. Acad. Sci. USA

    (1994)
  • W.E. Biddison et al.

    Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y

    Proc. Natl. Acad. Sci. USA

    (1977)
  • P.J. Bjorkman et al.

    Structure of the human class I histocompatibility antigen, HLA-A2

    Nature

    (1987)
  • R.A. Blades et al.

    Loss of HLA class I expression in prostate cancer: Implications for immunotherapy

    Urology.

    (1995)
  • O. Blanchet et al.

    Int. J. Cancer Suppl.

    (1991)
  • O. Blanchet et al.

    Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression

    Proc. Natl. Acad. Sci. USA

    (1992)
  • R.F. Bonner et al.

    Laser capture microdissection: Molecular analysis of tissue

    Science

    (1997)
  • T. Boon et al.

    Identification of tumour rejection antigens recognized by T lymphocytes

    Cancer Sure.

    (1992)
  • M.M. Bortin et al.

    Proc. first international symposium on alien histocompatibility antigens on cancer cells

    Transplant Proc.

    (1980)
  • M.M. Bortin et al.

    Proc. second international symposium on alien histocompatibility antigens on cancer cells

    Transplant Proc.

    (1981)
  • M.S. Brady et al.

    MHC class H-mediated antigen presentation by melanoma cells

    J. Immunother.

    (1996)
  • O. Braendstrup et al.

    Sertoli cells, but not tumor cells, of seminoma in situ express ICAM-1

    APMIS

    (1996)
  • J.P.J. Brakenhoff

    Interleukin-6 receptor antagonists

    Dig. Neurol. Psych.

    (1995)
  • P. Branch et al.

    Immune surveillance in colorectal carcinoma

    Nat Genet.

    (1995)
  • D. Brandle et al.

    A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma

    J. Exp. Med.

    (1996)
  • V. Braud et al.

    The human major histocompatibility complex class lb molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9

    Eur. J. Immunol.

    (1997)
  • V.M. Braud et al.

    HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

    Nature

    (1998)
  • V. Brichard et al.

    The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

    J. Exp. Med.

    (1993)

    • Cited by (0)

    View full text
    Copyright © 2000 Academic Press. Published by Elsevier Inc. All rights reserved.